NasdaqGM:RAPPPharmaceuticals
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing
In March 2026, Rapport Therapeutics reported a wider fourth-quarter and full-year 2025 net loss, while also filing new shelf registrations and granting Tenacia Biotechnology exclusive rights to develop and commercialize its clinical-stage candidate RAP-219 in Greater China in return for US$20 million upfront, potential milestone payments of about US$308 million, and tiered royalties.
This licensing deal, combined with plans for global Phase 3 trials of RAP-219 in focal onset seizures,...